Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | Explore a Market | Revisit recent analyses

Explore a new analysis by selecting an app below. On the next screen, select a cohort to use as the base for the analysis.

Purchased Packages

Key Insight

Cohort Explorer

Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Key Insight

Patient Journey

Understanding the details of all patient touchpoints within a specific healthcare experience.

Key Insight

Line of Therapy (LoT) Studies

Understand how patients progress across different lines of treatment and what is driving certain behaviors.

All Product Packages

View Cart

Key Insight

Adherence & Persistency

FREE 7-DAY TRIAL

Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Key Insight

Disease Progression

FREE 7-DAY TRIAL

Brief description

Key Insight

Market Landscape Study

FREE 7-DAY TRIAL

Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Key Insight

Patient Overview

FREE 7-DAY TRIAL

Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Key Insight

Payer Analysis

FREE 7-DAY TRIAL

Understanding how different healthcare payer's may influence the patient's treatment decisions.

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

Explore a new cohort based on a specific therapeutic market by launching the app from the options below.

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Purchased Markets

Key Insight
Cardiology
Brief description

Key Insight
Diabetes
Brief description

Key Insight
Oncology
Brief description

Key Insight
Rheumatoid Arthritis
Brief description

All Markets

Key Insight
Asthma
Brief description

Key Insight
Decongestant
Brief description

Key Insight
Endocrinology
Brief description

Key Insight
Epidemiology
Brief description

Key Insight
Dermatology
Brief description

Key Insight
Gastroenterology
Brief description

Key Insight
Hematology
Brief description

Key Insight
Immunology
Brief description

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

Diabetes Market

← Return to All Markets

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Key Performance Indicators

Clinical Outcomes

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc porttitor purus nec porttitor lobortis. More



Average Sales per Transaction

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc porttitor purus nec porttitor lobortis. More

Market Share

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc porttitor purus nec porttitor lobortis. More

Related Cohorts

Purchased

Cohort Name
Creator:
Number of patients:
Date modified:

Cohort Name
Creator:
Number of patients:
Date modified:

Cohort Name
Creator:
Number of patients:
Date modified:

Cohort Name
Creator:
Number of patients:
Date modified:

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | Explore a new market | **Revisit recent analyses**

Continue from a previous session.

Recent Activity

Name	App	Date Modified
Description/Name	Patient Journey	4-28-2022
Description/Name	**Cohort Explorer**	**4-23-2022**
Description/Name	Adherence & Persistency	4-15-2022
Description/Name	Line of Therapy Study	4-14-2022
Description/Name	Disease Progression	4-3-2022
Description/Name	Payer Analysis	3-29-2022
Description/Name	Market Landscape Study	3-20-2022
Description/Name	Adherence & Persistency	3-17-2022

Continue >

Resources

- Key Insights
- Predictive Insights
- Frequently Asked Questions
- Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

- Cohorts
  - Purchased
    - Diabetes
    - Rheumatoid Arthritis
  - Available
- Markets
  - Purchased
    - Cardiology
    - Diabetes
    - Oncology
    - Rheumatoid Arthritis
  - Available
- Submarkets
  - Purchased
    - Breast
    - Non-small Cell Lung
    - Hodgkin's Lymphoma
  - Available
    - Bladder
    - Cervical

Oncology Market

Explore a new cohort based on a specific therapeutic market by launching the app from the options below.

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Purchased Markets

Breast Brief description Key Insight	Lung, Non Small Cell Brief Description Key Insight	Lymphoma, Hodgkin's Brief description Key Insight

All Markets

Bladder Brief description Key Insight	Cervical Brief description Key Insight	CNS, Glioblastoma Brief description Key Insight
CNS, Medulloblastoma Brief description Key Insight	Colorectal Brief description Key Insight	Endometrial Brief description Key Insight
Esphogeal Brief description Key Insight	Gastric Brief description Key Insight	GIST Brief description Key Insight
Head/Neck Brief description Key Insight	Leukemia, Acute Lymphocytic Brief description Key Insight	Leukemia, Acute Myelogenous Brief description Key Insight

Resources

Key Insights	Predictive Insights	Frequently Asked Questions	Run Reports

Insights

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
APP
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
APP
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
APP
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
APP
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
APP
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec placerat iaculis mattis. Quisque tincidunt mattis enim, vitae venenatis.

Title/Headline
KPI

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

Oncology Market

Lung, Non-Small Cell

← Return to All Markets

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Key Performance Indicators

Leading cause

Lung cancer is the leading cause of death among men and women, making up more than 25% of cancer deaths. More



Commonality

NSCLC is the most common type of lung cancer, accounting for 85% of cases. More



Comorbidities

Approximately 50% of NSCLC patients have gone, which initiates cancer and contributes to growth. More

Related Cohorts

Lung Cancer Diagnosed Patients
Creator: Sally McGee
Number of patients: 252,403
Date modified: September 1, 2022

NSCLC with EGF
Creator: Mary Johnson
Number of patients: 48,595
Date modified: August 28, 2022

Multiple Myeloma Diagnosed Patients
Creator: Doug Jones
Number of patients:131,892
Date modified: August 11, 2022

Lung Cancer Diagnosed Patients Tested for PDL-1
Creator: John Smith
Number of patients: 76,501
Date modified: August 3, 2022

View all cohorts

Launch Cohort

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence
from Symphony Health

Non Small Cell

- **Non Small Cell Lung Cancer**
- Line of Therapy
- Patient Journey
- Oncology Cohort
- Diabetes Market

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | Explore a Market | Revisit recent analyses

Explore a new analysis by selecting an app below. On the next screen, select a cohort to use as the base for the analysis.

Key Insight
Adherence & Persistency
Brief description

Key Insight
Cohort Builder
Brief description

Key Insight
Cohort Explorer
Brief description

Key Insight
Disease Progression
Brief description

Key Insight
Line of Therapy (LoT) Studies
Brief description

Key Insight
Market Landscape Study
FREE 7-DAY TRIAL
Brief description

Key Insight
Payer Analysis
Brief description

Key Insight
Patient Journey
Brief description

Resources

- Key Insights
- Predictive Insights
- Frequently Asked Questions
- Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

Explore a new cohort based on a specific therapeutic market by launching the app from the options below.

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Purchased Markets

Key Insight
Cardiology
Brief description

Key Insight
Diabetes
Brief description

Key Insight
Oncology
Brief description

Key Insight
Rheumatoid Arthritis
Brief description

All Markets

Key Insight
Asthma
Brief description

Key Insight
Decongestant
Brief description

Key Insight
Endocrinology
Brief description

Key Insight
Epidemiology
Brief description

Key Insight
Dermatology
Brief description

Key Insight
Gastroenterology
Brief description

Key Insight
Hematology
Brief description

Key Insight
Immunology
Brief description

Key Insight
Infectious Disease
Brief description

Key Insight
Iron Deficiency
Brief description

Key Insight
Mental Health
Brief description

Key Insight
Neurology
Brief description

Key Insight
Ophthalmology
Brief description

Key Insight
Osteoporosis
Brief description

Key Insight
Pain Management
Brief description

Key Insight
Ulcerative Colitis
Brief description

Key Insight
Urology
Brief description

Key Insight
Vitamin D
Brief description

Key Insight
Women's Health
Brief description

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | Explore a Market | Revisit recent analyses

Explore a new analysis by selecting an app below. On the next screen, select a cohort to use as the base for the analysis.

Purchased Packages

Key Insight

Line of Therapy (LoT) Studies

Brief description

All Product Packages

View Cart

Key Insight

Adherence & Persistency

FREE 7-DAY TRIAL

Brief description

Key Insight

Cohort Explorer

FREE 7-DAY TRIAL

Brief description

Key Insight

Disease Progression

FREE 7-DAY TRIAL

Brief description

Key Insight

Market Landscape Study

FREE 7-DAY TRIAL

Brief description

Key Insight

Payer Analysis

FREE 7-DAY TRIAL

Brief description

Key Insight

Patient Journey

FREE 7-DAY TRIAL

Brief description

Resources

Key Insights

Predictive Insights

Frequently Asked Questions

Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Non Small Cell

- **Non Small Cell Lung Cancer**
- Line of Therapy
- Patient Journey
- Oncology Cohort
- Diabetes Market

Patient Intelligence

Select a study to launch, then select a cohort.

Search Results

LINE OF THERAPY APP
Non Small Cell Lung Cancer - LoT 1

COHORT
Non Small Cell Lung Cancer

PATIENT JOURNEY APP
Non Small Cell Lung Cancer

COHORT
NSCLC

COHORT
NSC Lung Cancer

Resources

- Key Insights
- Predictive Insights
- Frequently Asked Questions
- Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

Start a new analysis | **Explore a new market** | Revisit recent analyses

Oncology Market

Explore a new cohort based on a specific therapeutic market by launching the app from the options below.

Key Insights

Global Oncology Market is expected to reach $2,74,401 Million by 2030,growing at a CAGR of 7.5%.

Oncology Markets

Breast
Brief description
Key Insight

Lung, Non Small Cell
Brief Description
Key Insight

Lymphoma, Hodgkin's
Brief description
Key Insight

All Markets

Bladder
Brief description
Key Insight

Cervical
Brief description
Key Insight

CNS, Glioblastoma
Brief description
Key Insight

CNS, Medulloblastoma
Brief description
Key Insight

Colorectal
Brief description
Key Insight

Endometrial
Brief description
Key Insight

Esphogeal
Brief description
Key Insight

Gastric
Brief description
Key Insight

GIST
Brief description
Key Insight

Head/Neck
Brief description
Key Insight

Leukemia, Acute Lymphocytic
Brief description
Key Insight

Leukemia, Acute Myelogenous
Brief description
Key Insight

Leukemia, Chronic Lymphocytic
Brief description
Key Insight

Leukemia, Chronic Myelogenous
Brief description
Key Insight

Liver
Brief description
Key Insight

Lung Cancer, Small Cell
Brief description
Key Insight

Lymphoma, Non-Hodgkin's
Brief description
Key Insight

Melanoma
Brief description
Key Insight

Mesothelioma
Brief description
Key Insight

Metastatic Cancer
Brief description
Key Insight

Multiple Myeloma
Brief description
Key Insight

Myelodysplastic Syndrome
Brief description
Key Insight

Myeloproliferative Neoplasms
Brief description
Key Insight

Neuroendocrine
Brief description
Key Insight

Ovarian
Brief description
Key Insight

Pancreas
Brief description
Key Insight

Prostate
Brief description
Key Insight

Renal
Brief description
Key Insight

Skin, Basal Cell Carcinoma
Brief description
Key Insight

Soft Tissue Sarcoma
Brief description
Key Insight

Supportive Care
Brief description
Key Insight

Testicular
Brief description
Key Insight

Thyroid
Brief description
Key Insight

Unspecified Cancer
Brief description
Key Insight

Unspecified Solid Tumor
Brief description
Key Insight

Resources

Key Insights
Predictive Insights
Frequently Asked Questions
Run Reports

Insights

Lung Cancer is by far the leading cause of cancer death
KPI
Lung Cancer is by far the leading cause of cancer death among men and women, making up more than 25% of cancer deaths

NSCLC is the most common type of lung cancer
KPI
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases

Approximately 50% of NSCLC patients have oncogene
KPI
Approximately 50% of NSCLC patients have oncogene, that initiates cancer and contribute to growth.

Treatment with targeted therapy
KPI
Treatment with targeted therapy is associated with improved outcomes for patients.

Adherence & Persistency
APP
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Market Landscape Study
APP
Understanding the dynamics of a market, including volume and value, potential customer segments, sales/revenue, competition, and other important factors.

Patient Overview
APP
Understanding a patient's profile, including age, gender, income, ethnicity and geographic distribution.

Payer Analysis
APP
Understanding how different healthcare payer's may influence the patient's treatment decisions.

Patient Journey
APP
Understanding the details of all patient touchpoints within a specific healthcare experience.

Line of Therapy
APP
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Cohort Explorer
APP
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Patient Intelligence

Select a study to launch, then select a cohort.

View Cart

Adherence & Persistency

Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

$XX.XX



Dermatology Market

Understanding the details of all patient touchpoints within a specific healthcare experience.

$XX.XX

Acne Cohort

Understanding the details of all patient touchpoints within a specific healthcare experience.

$XX.XX

Subtotal	$XX.XX
Tax	$XX.XX
Total	**$XX.XX**

Proceed to Checkout

Suggested Apps and Cohorts

Line of Therapy Treatments

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

LoT Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product

Metrics

Total Patient Volume by Line



Product Share by Line



Total Patient Volume by Product



Total Patient Share by Product (L1 with Maintenance)



Total Patient Share by Product (L3)



New Patient Volume by Line



New to Brand Patient Volume by Product



Proportion of Patients Treated Across Different Lines of Therapy



Proportion of Patients per Regimen by Line

Select a Cohort

To explore a Patient Journey, select one or more cohorts.

Advanced search

Sort

Created by Symphony >

Lung Cancer Diagnosed Patients
Creator:
Number of patients: 252,403
Date modified:
Launch App

NSCLC with EGF
Creator:
Number of patients: 48,595
Date modified:
Launch App

Multiple Myeloma Diagnosed Patients
Creator:
Number of patients:131,892
Date modified:
Launch App

Lung Cancer Diagnosed patients tested for PDL-1
Creator:
Number of patients: 76,501
Date modified:
Launch App

Browse by Therapeutic Area >

NSCLC
Number of patients:
Study period:
Data source:
Launch App

SCLC
Creator:
Number of patients:
Date modified:
Launch App

Heart Disease
Creator:
Number of patients:
Date modified:
Launch App

Lung Cancer
Creator:
Number of patients:
Date modified:
Launch App

Cancel

Launch

Patient Journey

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Insights | **Details** | Timing



Adjust Threshold 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

- Diagnostic Test: X-ray
  47% of patients has 3 or more test/procedures prior to diagnosis.
- Comorbidities: Hypertension
  43% of patients presented with 3+ comorbidities before receiving a lung cancer diagnosis.
- Prescriptions
  52% of NSCLC patients received antibiotics, steroids to treat severe pain, infections, and stomach ulcers prior to diagnosis.
- Practitioner Specialty: Internal Medicine
- Geographic Distribution: Population



View full metrics

Patient Journey

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Insights | Details | Timing



Adjust Threshold 12,345 198,765 (0 – 249,301)

KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

- Diagnostic Test: X-ray
  47% of patients has 3 or more test/procedures prior to diagnosis.
- Comorbidities: Hypertension
  43% of patients presented with 3+ comorbidities before receiving a lung cancer diagnosis.
- Prescriptions
  52% of NSCLC patients received antibiotics, steroids to treat severe pain, infections, and stomach ulcers prior to diagnosis.
- Practitioner Specialty: Internal Medicine
- Geographic Distribution: Population



View full metrics

Line of Therapy Treatments

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

LoT Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product

Metrics

Total Patient Volume by Line



Product Share by Line



Total Patient Volume by Product



Total Patient Share by Product (L1 with Maintenance)



Total Patient Share by Product (L3)



New Patient Volume by Line



New to Brand Patient Volume by Product



Proportion of Patients Treated Across Different Lines of Therapy



Proportion of Patients per Regimen by Line

Line of Therapy

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

LoT Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product

Line of Therapy Overview

METRIC VIEW | **FLOW VIEW**



KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

Diagnostic Test: X-ray

47% of patients has 3 or more test/procedures prior to diagnosis.

Comorbidities: Hypertension

43% of patients presented with 3+ comorbidities before receiving a lung cancer diagnosis.

Prescriptions

52% of NSCLC patients received antibiotics, steroids to treat severe pain, infections, and stomach ulcers prior to diagnosis.

Practitioner Specialty: Internal Medicine

Geographic Distribution: Population



View full metrics

Line of Therapy

Non-Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

LoT Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product

METRIC VIEW | FLOW VIEW

DIAGNOSIS — **LINE 1** — LINE 2 — LINE 3 — LINE 4

Add panel
Remove panel
Remove as anchor point

Pre-Treatment (Diagnosis)

Diagnostic Specialty

Type	Percent
Dermatologist	58%
PCP	8%
NP/PA	6%
Pedetrician	6%
Other	10%

Patient Demographics

Gender

38% Male
62% Female

Age

0–8	0
9–12	1%
13–16	18%
17–20	36%
21–24	10%

Time between first diagnosis and first treatment

First Treatment: Doxycycline Hyclate

1st Tx – 30.3K Pts

*Note: Patients receiving product as first treatment in first seven days within first diagnosis

Timing

38% Patients on first treatment for 30 days or 30–60 days

Primary Specialty

Type	Percent
Dermatologist	24%
Pedetrician	5%
PCP	24%
NP/PA	24%
Other	16%

Secondary Specialty



Top Five Combination Treatments

Mono (12%)
Combination (88%)

Combination Treatments

- Clindamycin Phosphate (26%)
- Tretinoin (26%)
- Adapalene (8%)
- Clindamycin Phosphate (6%)
- Epiduo (4%)

Second Treatment

Discontinue Treatment

42% Patients

Continue Treatment

37% Patients

Switch Treatment

21% Patients



Median days between first Tx to switch

Clindamycin Phosphate	Tretinoin	Doxycycline Monohydrate	Minocycline HCL	Adapalene
80	56	198	118	38

Add-on Treatment

0.01% Patients

KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

Diagnostic Test: X-ray

47% of patients has 3 or more test/procedures prior to diagnosis.

Comorbidities: Hypertension

43% of patients presented with 3+ comorbidities before receiving a lung cancer diagnosis.

Prescriptions

52% of NSCLC patients received antibiotics, steroids to treat severe pain, infections, and stomach ulcers prior to diagnosis.

Practitioner Specialty: Internal Medicine

Geographic Distribution: Population



View full metrics

Line of Therapy

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

Lines of Therapy Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product
- Total Patient Share by Product (L1 with Maintenance)

Line of Therapy Overview



Geographic Distribution

Close

LEGEND

- Discontinue treatment
- Continue treatment
- Switch treatment
- Add-on treatment

KEY METRIC HIGHLIGHTS

Demographics

- Gender
- Age
- Income
- Education
- Ethnicity

Pre-Diagnosis

Diagnostic Tests

47% of patients had 3 or more diagnostic tests/ procedures prior to Diagnosis

Comorbidities

43% of patients present with 3+ comorbidities in the year before lung cancer diagnosis

Prescriptions

52% of NSCLC patients received antibiotics, steroids to treat severe pain, infections and stomach ulcers prior to diagnosis.

Practitioner Specialty



View full metrics

Line of Therapy

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

Lines of Therapy Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product
- Total Patient Share by Product (L1 with Maintenance)

Line of Therapy Overview

METRIC VIEW | **FLOW VIEW**



KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

- Diagnostic Test: X-ray
- Comorbidities: Hypertension
- Practitioner Specialty: Internal Medicine
- Geographic Distribution: Population



View full metrics

Patient Journey

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Pre-Diagnosis Analysis

- Distribution of Top Comorbidities
- Disease Specific Comorbidities
- Comorbidities prior to Diagnosis
- Constitutional Comorbidities
- Distribution of Chlarson Comorbidities

Treatment Timing Analysis

- Time between Diagnosis and First Treatment
- Diagnostic Testing
- Survival Rates from Time to Treatment
- Constitutional Comorbidities
- Time between 1L Discontinuation & 2L Initiation
- Time between 2L Discontinuation & 3L Initiation
- Time between Lines
- Time to Progression
- Median Survival
- Treatment across LoT

LoT Metrics

- Total Patient Volume by Line
- Product Share by Line
- Total Patient Volume by Product

Line of Therapy Overview

METRIC VIEW | **FLOW VIEW**



KEY METRIC HIGHLIGHTS

Demographics

- Gender: Male
- Age: 31–40 years
- Income: $75K–99K
- Education: Bachelor's
- Ethnicity: Caucasian

Pre-Diagnosis

- Diagnostic Test: X-ray
- Comorbidities: Hypertension
- Practitioner Specialty: Internal Medicine
- Geographic Distribution: Population



View full metrics

Select a Cohort

Select a base cohort to explore. Cohorts can be modified and saved as new sub-cohorts.

Advanced search

Sort

Created by Symphony >

Lung Cancer Diagnosed Patients
Number of patients : 61,623,327
Study Period : 2010 to 2017
Data Source: Claims

Launch App

NSCLC with EGF
Number of patients : 48,595,02
Study Period : 2015 to 2020
Data Source: Claims, Lab

Launch App

Multiple Myeloma Diagnosed Patients
Number of patients : 13,892,10
Study Period : 2016 to 2021
Data Source: Claims, EMR

Launch App

Lung Cancer Diagnosed Patients Tested for PDL-1
Number of patients : 76,501,22
Study Period : 2015 to 2022
Data Source: Claims, EMR, Lab

Launch App

Browse by Therapeutic Area >

NSCLC
Number of patients : 61,623,327
Study Period : 2010 to 2017
Data Source: Claims

Launch App

SCLC
Number of patients : 48,595,02
Study Period : 2015 to 2020
Data Source: Claims, Lab

Launch App

Heart Disease
Number of patients : 13,892,10
Study Period : 2016 to 2021
Data Source: Claims, EMR

Launch App

Lung Cancer
Number of patients : 76,501,22
Study Period : 2015 to 2022
Data Source: Claims, EMR, Lab

Launch App

Cancel

Launch

Select a Cohort

Select a base cohort to explore. Cohorts can be modified and saved as new sub-cohorts.

Advanced search

Sort

- Cohort name (A–Z)
- Cohort name (Z–A)
- Creator
- Date modified (newest)
- Date modified (oldest)
- Number of patients (high to low)
- Number of patients (low to high)
- Therapeutic area (A–Z)
- Therapeutic area (Z–A)

Created by Symphony >

Cohort Name
Creator:
Number of patients:
Date modified:
Launch App

Cohort Name
Creator:
Number of patients:
Date modified:
Launch App

Cohort Name
Creator:
Number of patients:
Date modified:
Launch App

Cohort Name
Creator:
Number of patient
Date modified:
Launch App

Browse by Therapeuti

Cohort Name
Creator:
Number of patients:
Date modified:
Launch App

me
atients:
d:

Launch App

Adherence & Persistency
Understanding how long patients are staying on a therapy and being compliant to the prescribed regimen/medication.

Cohort Explorer
Application designed to support rapid querying and reporting to discover patient trends and encounter populations.

Line of Therapy
Understand how patients progress across different lines of treatment and what is driving certain behaviors.

Patient Journey
Understanding the details of all patient touchpoints within a specific healthcare experience.

Launch

Cancel Launch

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

Demographics

Gender

Female	542
Male	627
Other	128

Age

70	473
60	365
50	279
40	113
30	67

Education

Pre-Diagnosis

- Comorbidities
- Location
- Practitioner Type
- Prescriptions
- Test Type
- Time

Diagnosis

Treatment

Explore more data dimensions by adding to the existing panel

- or -

Create a new panel to explore from the options on the left.

- or -

Launch an app based off this cohort explorer.

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

Demographics

Gender
- Female 542
- Male 627
- Other 128

Age
- 70 473
- 60 365
- 50 279
- 40 113
- 30 67

Education

Pre-Diagnosis

- Comorbidities
- Location
- Practitioner Type
- Prescriptions
- Test Type
- Time

Diagnosis

Treatment

Demographics

Key Performance Indicators

NSCLC Patients have a greater proportion of male patients over the age of 65.

View more

Predictive Analytics

Male patients are most likely to be at risk based on the existing comorbidities.

Gender

Explore more data dimensions by adding to the existing panel

- or -

Create a new panel to explore from the options on the left.

- or -

Launch an app based off this cohort explorer.

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

Demographics

Gender
- Female 542
- Male 627
- Other 128

Age
- 70 473
- 60 365
- 50 279
- 40 113
- 30 67

Education

Pre-Diagnosis

- Comorbidities
- Location
- Practitioner Type
- Prescriptions
- Test Type
- Time

Diagnosis

Treatment

Demographics

Key Performance Indicators

Predictive Analytics

ICON Text

Gender

Ma
n=6

Customize Age Group

- [ ] < 29 years old
- [x] 30–39 years old
- [x] 40–49 years old
- [x] 50–59 years old
- [ ] 60–69 years old
- [ ] 70–79 years old
- [ ] < 80 years
- [ ] All groups



Apply Clear

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

Demographics

Gender
- Female 542
- Male 627
- Other 128

Age
- 70 473
- 60 365
- 50 279
- 40 113
- 30 67

Education

Pre-Diagnosis
- Comorbidities
- Location
- Practitioner Type
- Prescriptions
- Test Type
- Time

Diagnosis

Treatment

Demographics

Key Performance Indicators

Predictive Analytics

View Detailed Dashboard

Gender

Age Group



Explore more data components by adding to the existing panel

- or -

Create a new panel to explore from the options on the left.

- or -

Launch an app based off this cohort explorer.

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
  - Comorbidities
    - Diabetes 473
    - Heart Disease 365
    - Hypertension 279
    - Bronchitis 113
    - Stroke 67
  - Location
  - Practitioner Type
  - Practitioner Type
  - Prescriptions
  - Test Type
- Diagnosis
- Treatment

Demographics

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Gender

Age Group

Pre-Diagnosis

- Collapse panel
- Expand panel
- Remove panel

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Test Type

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are
on the left. To customize n
filters, use the settings icon
the card.

Search

Demographics

Pre-Diagnosis

Comorbidities

Diabetes

Heart Disease

Hypertension

Bronchitis

Stroke

Location

Practitioner Type

Practitioner Type

Prescriptions

Test Type

Diagnosis

Treatment

Demographics

Pre-Diagnosis

Add Comorbidities

Hyper

Hypertension
Hyperthyroidism
Hyperthermia
Hypertonic cardiomyopathy

- [ ] COPD
- [ ] Chronic kidney disease
- [ ] Depression
- [ ] Diabetes
- [ ] Heart disease
- [ ] Hypertension
- [ ] Hyperthyroidism
- [ ] Hypothyroidism
- [ ] Myocardial infarction
- [ ] Peripheral arterial disease
- [ ] Pneumonia
- [ ] Pulmonary embolism
- [ ] Stroke
- [ ] Tuberculosis



Apply

Clear

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
  - Comorbidities
    - Diabetes 473
    - Heart Disease 365
    - Hypertension 279
    - Bronchitis 113
    - Stroke 67
  - Location
  - Practitioner Type
  - Practitioner Type
  - Prescriptions
  - Test Type
- Diagnosis
- Treatment

Demographics

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Gender

Age Group



Pre-Diagnosis

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Test Type

Comorbidities



Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Set

Drag a card to the right to view full data set.

Search

Demographics

Pre-Diagnosis

Comorbidities
67% had 3+ comorbiditi

Location
58% visited outpatient c

Practitioner Type
72% Primary Care Phys

Prescriptions
32% filled

Test Type
91% received X-Rays

Diagnosis

Treatment

Demographics

Key Performance Indicators

Predictive Analytics

Pre-Diagnosis

Key Performance Indicators

Predictive Analytics

Comorbidities



Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
- Diagnosis
  - Costs
  - Location
    - Hospital 473
    - Clinic 365
    - Medical Office 279
    - Urgent Care Facility 113
    - Other 67
  - Practitioner Type
  - Prescriptions
  - Time
- Treatment

aphics

rs

40–49 years
n=306

Pre-Diagnosis

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Test Type

Comorbidities

- Arrythmia (72)
- Atelectasis (31)
- Atrial fibrillation (16)
- **Bronchitis (300)**
- Cancer (116)
- COPD (276)
- Chronic kidney disease (157)
- Depression (301)
- Diabetes (412)
- Heart disease (404)
- Hypertension (386)
- Hyperthyroidism (219)

Diagnosis

- Key Performance Indicators
- Predictive Analytics
- View Detailed Dashboard

Practitioner Type

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
- Diagnosis
- Treatment
  - Claims
  - Out-of-Pocket Costs
  - Lines of Therapy
    - 3+ 542
    - 2+ 627
    - 1 128
  - Prescriptions
  - Practitioner Type

osis

Diagnosis

- Key Performance Indicators
- Predictive Analytics

Practitioner Type

Treatment Initiation

- Key Performance Indicators
- Predictive Analytics

Claims Approval

Out-of-Pocket Costs

Practitioner Type

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer: Demographics

Return to App

Total number of patients

8,762,661 +0.8%

30 day change

Newly diagnosed patients this month

42,715 +3.8%

30 day change

Patient gender distribution

64% Female

36% Male

1 month | 3 months | 6 months | 12 months | 24 months | YTD

Cohort: Name x

Patient ethnicity distribution

- Asian (52)
- Black/African-American (182)
- Caucasian (341)
- Hispanic(117)
- Missing (286
- Other (106)

Patient age distribution

- > 30 years (51)
- 31–40 years (215)
- 41–50 years (306)
- 51–60 years (104)
- 61–70 years (110)
- 71–80 years (86)
- < 81 years (42)

Newly diagnosed patients trend



Patient education distribution

- High School (31)
- Some College (114)
- Associate's Degree (356)
- Bachelor's Degree (217)
- Master's (289)
- Doctorate (102)
- Unspecified (188)

Patient income distribution

- > $30K
- $30,001–40K
- $40,001–50K
- $51,001–60K
- $60,001–70K
- $70,001–80K
- $80,001–90K
- $91,011–100K
- $100,001–110K
- $110,001–120K
- < $120K

Patient geographic distribution (normalized to population)



Patient Intelligence Cohort Explorer

Untitled Cohort

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
  - Comorbidities
    - Diabetes 473
    - Heart Disease 365
    - Hypertension 279
    - Bronchitis 113
    - Stroke 67
  - Location
  - Practitioner Type
  - Practitioner Type
  - Prescriptions
  - Test Type
- Diagnosis
- Treatment

Demographics

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus sed nunc ante. Morbi dui neque, lobortis id porttitor quis, eleifend id arcu. Suspendisse sit amet urna.

ICON Text ICON Text

ICON Text

ICON Text

Predictive An

Lorem ipsum
Phasellus se
porttitor quis

Gender: Male

Age Group: 31–



Pre-Diagnosis

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus sed nunc ante. Morbi dui neque, lobortis id porttitor quis, eleifend id arcu. Suspendisse sit amet urna.

ICON Text ICON Text



Add Data Set

- [ ] Comorbidities
- [ ] Historical Diagnosis
- [ ] Practitioner
- [ ] Prescriptions
- [x] Test Type
- [ ] View All



Apply Clear

Patient Intelligence Cohort Explorer

Untitled Cohort

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

- Demographics
- Pre-Diagnosis
  - Comorbidities
    - Diabetes 473
    - Heart Disease 365
    - Hypertension 279
    - Bronchitis 113
    - Stroke 67
  - Location
  - Practitioner Type
  - Practitioner Type
  - Prescriptions
  - Test Type
- Diagnosis
- Treatment

Demographics

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus sed nunc ante. Morbi dui neque, lobortis id porttitor quis, eleifend id arcu. Suspendisse sit amet urna.

ICON Text ICON Text
ICON Text ICON Text
ICON Text ICON Text

Predictive Analytics

Lorem ipsum dolor sit amet, c
Phasellus sed nunc ante. Mor
porttitor quis, eleifend id arcu.

Gender: Male

Age Group: 31–60 years



Pre-Diagnosis

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus sed nunc ante. Morbi dui neque, lobortis id porttitor quis, eleifend id arcu. Suspendisse sit amet urna.

ICON Text ICON Text
ICON Text ICON Text
ICON Text ICON Text

Predictive Analytics

dipiscing elit.
lobortis id
sit amet urna.

Comorbidities



Save As New Cohort Exploration

Cohort name:

Save Clear

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Add Data Dimension

Drag a card to the right to view full data dimension.

Only the top five filters are visible on the left. To customize more filters, use the settings icon (⚙) in the card.

Search

Demographics

Gender

Female 542

Male 627

Other 128

Age

70 473

60 365

50 279

40 113

30 67

Education

Pre-Diagnosis

Comorbidities

Location

Practitioner Type

Prescriptions

Test Type

Time

Diagnosis

Treatment

Demographics

Key Performance Indicators

NSCLC Patients have a greater proportion of male patients over the age of 65.

View more

Predictive Analytics

Male patients are most likely to be at risk based on the existing comorbidities.

Gender

Version	Patients	Rx	Dx	Sx	Px
0	3,000,000	1,000,000	2,000,000	1,000,000	9,000,000
1	50	150	27	12	450
2	30	95	20	8	219
3	15	60	18	7	175
4	10	47	12	5	88
5	5	13	6	3	51

Px
Sx
Dx
Rx
Patients
2500

Explore more data dimensions by adding to the existing panel

- or -

Create a new panel to explore from the options on the left.

- or -

Launch an app based off this cohort explorer.

Patient Intelligence Cohort Explorer

Non Small Cell Lung Cancer

Gender: Comparison

Version	Patients	Rx	Dx	Sx	Px
0	3,000,000	1,000,000	2,000,000	1,000,000	9,000,000
1	50	150	75	22	450
2	30	95	32	17	557
3	15	60	20	14	219
4	10	47	15	7	175
5	5	13	8	3	59



Practitioner Type

Prescriptions

Test Type

Time

Diagnosis

Treatment

Adherence & Persistency

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Kaplan-Meier Curve | Cox-Hazard Data | KPI Drivers

CHART VIEW | TABLE VIEW

Compare
- Gender
- Income
- Setting
- Physician Specialty
- Payer Costs

Male
Female
Other
Apply



Legend

Demographics
- Age
- Education
- Ethnicity
- Gender
- Income

Diagnosis/Treatment
- Comorbidities
- Cost
- Physician Specialty
- Setting
- Test Type

Confidence Interval 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics
- Gender
- Age
- Income
- Education
- Ethnicity

Pre-Diagnosis
- Diagnostic Tests
- Comorbidities
  - Arrythmia (72)
  - Atelectasis (31)
  - Atrial fibrillation (16)
  - Bronchitis (300)
  - Cancer (116)
  - COPD (276)
  - Chronic kidney disease (157)
  - Depression (301)
  - Diabetes (412)
  - Heart disease (404)
  - Hypertension (386)
  - Hyperthyroidism (219)
- Practitioner Specialty



View full metrics

Adherence & Persistency

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Kaplan-Meier Curve | Cox-Hazard Data | KPI Drivers

Compare

CHART VIEW | DATA VIEW

Patient Persistency

Overall	Patient Count	Cum Patients	Persistency
M0	6	23	100%
M1	2	17	74%
M2	2	15	65%
M3	1	13	57%
M4	2	12	52%
M5	2	10	43%
M6	0	8	35%
M7	0	8	35%
M8	1	8	35%
M9	1	7	30%
M10	2	6	26%
M11	2	4	17%
M12	2	2	9%

Overall Monthly Persistency



Total Patients: 23

Confidence Interval 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics

- Gender
- Age
- Income
- Education
- Ethnicity

Pre-Diagnosis

- Diagnostic Tests
- Comorbidities



- Practitioner Specialty



View full metrics

Adherence & Persistency

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

Demographics

Gender
- Female 124,650
- Male 99,721
- Other 24,930

Age
- 70 124,650
- 60 99,721
- 50 24,930
- 40 24,930
- 30 24,930

Income

Education

Pre-Diagnosis

Comorbidities

Diagnostic Tests

Practitioner Specialty

Prescriptions

Diagnosis

Setting

Practitioner Specialty

Payer Metrics

Prescriptions

Kaplan-Meier Curve | **Cox-Hazard Data** | KPI Drivers

Compare

CHART VIEW | **TABLE VIEW**

Driver Category	Driver	Coefficient	Hazard Ratio	z Value	Pr(> |z|)
Disease	Diagnosis history	0	1.442	2.042	0.0041
	Previous treatment experience	0.203	1.225	1.436	0.151
	Previous market treatment experience	-0.402	0.669	-1.952	0.051
	Comorbidities/side effects/complications	0.163	1.177	1.279	0.201
Patient	Gender distribiution	0.303	1.354	2.194	0.028
	Age distribution	0.52	1.682	2.333	0.02
	Ethnicity distribution	0.244	1.276	1.596	0.111
	Geographic distribution	0.415	1.514	1.879	0.06
	Income distribution	0.244	1.276	1.432	0.152
	Income between $50K and $74K	0.253	1.288	1.604	0.109
	Income between $75K and $99K	-0.382	0.682	-1.89	0.059
	Income >= $100K	0.303	1.354	1.932	0.063
	Dosage frequency (high/medium/low)	0.163	0.73	-2.204	0.028
	Adherence profile (MPR percentage)	-1.96	0.141	-13.369	< 2e-16
Payer	Change in health plan	-0.232	0.793	-1.649	0.099
	Payment type	0.196	1.204	1.462	0.144
	Average out-of-pocket expenses	-0.227	0.797	-1.804	0.071
	PA duration	0.381	0.683	-2.119	0.034
	Total patient pay high	0.385	0.784	-2.004	0.044
	Brand level persistency	-1.471	0.232	-2.878	0.004
Physician	Physician specialty	-0.331	0.718	-2.136	0.033
	Place of service	-0.264	0.768	-1.636	0.102

Confidence Interval 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics

Gender >

Age >

Income >

Education >

Ethnicity >

Pre-Diagnosis

Diagnostic Tests >

Comorbidities



Practitioner Specialty



View full metrics

Adherence & Persistency

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Kaplan-Meier Curve | **Cox-Hazard Data** | KPI Drivers

Compare

CHART VIEW | TABLE VIEW



Confidence Interval 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics

- Gender
- Age
- Income
- Education
- Ethnicity

Pre-Diagnosis

- Diagnostic Tests
- Comorbidities



- Practitioner Specialty



View full metrics

Adherence & Persistency

Non Small Cell Lung Cancer

Filter Component

Drag a card to the right to view full data set.

Search

- Demographics
  - Gender
    - Female 124,650
    - Male 99,721
    - Other 24,930
  - Age
    - 70 124,650
    - 60 99,721
    - 50 24,930
    - 40 24,930
    - 30 24,930
  - Income
  - Education
- Pre-Diagnosis
  - Comorbidities
  - Diagnostic Tests
  - Practitioner Specialty
  - Prescriptions
- Diagnosis
  - Setting
  - Practitioner Specialty
  - Payer Metrics
  - Prescriptions

Kaplan-Meier Curve | Cox-Hazard Data | KPI Drivers

Compare

Aged over 65

Patient age over 65 **decreases** the risk of discontinuation compared to patients age <65.

Geographic Location

Geographical location of patients may affect persistence on therapy

Higher Income

Patient household income between **$75k–$99k decreases** the risk of discontinuation.

Patient Persistence

Patients who are highly complaint (measured using MPR) on other medications used may be more persistent with Therapy/Treatment.

Patient Persistence

Patients who are highly complaint (measured using MPR) on other medications used may be more persistent with Therapy/Treatment.

Dosing Regimen/Frequency

Therapy/Treatment starting doses impacts patients persistence, patients on higher dose may be more persistent with treatment.

Lower Income

Patient household income <$30k **increases** the risk of discontinuation.

Aged over 65

Patient age under 65 **increases** the risk of discontinuation.

Confidence Interval 12,345 198,765 0 249,301

KEY METRIC HIGHLIGHTS

Demographics

- Gender
- Age
- Income
- Education
- Ethnicity

Pre-Diagnosis

- Diagnostic Tests
- Comorbidities
  - Arrythmia (72)
  - Atelectasis (31)
  - Atrial fibrillation (16)
  - Bronchitis (300)
  - Cancer (116)
  - COPD (276)
  - Chronic kidney disease (157)
  - Depression (301)
  - Diabetes (412)
  - Heart disease (404)
  - Hypertension (386)
  - Hyperthyroidism (219)
- Practitioner Specialty



View full metrics